-
Innovation Ranking
NewInnovation Ranking – PTC Inc
PTC Inc (PTC), is a developer of software products and related services. The company offers product lifecycle management (PLM), computer-aided design (CAD), augmented reality (AR), internet-of-things (IoT), application lifecycle management (ALM) products, service lifecycle management (SLM) products, and service parts management software, and related services. It provides services such as maintenance, implementation, advisory, consulting, and cloud-based services. PTC serves aerospace and defense, life sciences, electronics and high-tech, energy and resources, retail, consumer products, industrial machinery, process industries, and automotive industries....
-
Innovation Ranking
NewInnovation Ranking – PTC Therapeutics Inc
PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and markets medicines for the treatment of rare disorders. Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy, Translarna (ataluren) and Emflaza (deflazacort) for the treatment of Duchenne muscular dystrophy. The company's pipeline candidates target the treatment of Huntington’s disease; children with inherited mitochondrial disease; leiomyosarcoma; acute myelogenous leukemia; and aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. It...
-
Product Insights
NewNet Present Value Model: PTC Therapeutics Inc’s PTC-518
Empower your strategies with our Net Present Value Model: PTC Therapeutics Inc's PTC-518 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: PTC Therapeutics Inc’s Vincerinone
Empower your strategies with our Net Present Value Model: PTC Therapeutics Inc's Vincerinone report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: PTC Therapeutics Inc’s Sepiapterin
Empower your strategies with our Net Present Value Model: PTC Therapeutics Inc's Sepiapterin report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Sector Analysis
ERCP and PTC Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
ERCP and PTC Devices Market Report Overview The ERCP and PTC devices market size was $913.9 million in 2023. The market is expected to grow at a CAGR of more than 2% during 2023-2033. Endoscopic Retrograde Cholangiopancreatography (ERCP) is a combined endoscopic and radiologic procedure for the ducts draining the liver and pancreas, which includes bile ducts, gallbladder, and pancreatic ducts. Meanwhile, Percutaneous Transhepatic Cholangiography (PTC) is useful in accessing the biliary tree when a high-grade stricture precludes endoscopic visualization...
-
Product Insights
Jaora-PTC
Jaora-PTC is an Onshore Wind project located in Madhya Pradesh, India. The project is owned and developed by PTC India Ltd. The project came online in 2016. Empower your strategies with our Jaora-PTC report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered...
-
Product Insights
NewLikelihood of Approval Analysis for Papillary Thyroid Cancer
Overview How likely is it that the drugs in Papillary Thyroid Cancer will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Papillary Thyroid Cancer Overview Papillary thyroid cancer (PTC) is the most...
-
Product Insights
NewNet Present Value Model: PTC Therapeutics Inc’s Utreloxastat
Empower your strategies with our Net Present Value Model: PTC Therapeutics Inc's Utreloxastat report and make more profitable business decisions. Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...